Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 Andrew M. Brunner, MD, Shuli Li, Amir T. Fathi, MD, Vincent T. Ho, MD, Richard M. Stone, MD, Robert J. Soiffer, MD, Yi-Bin Chen, MD Biology of Blood and Marrow Transplantation Volume 22, Issue 3, Pages S198-S199 (March 2016) DOI: 10.1016/j.bbmt.2015.11.588 Copyright © 2016 Terms and Conditions
Figure 1 Disease-free and Overall Survival for FLT3-ITD AML patients, with or without sorafenib maintenance after HCT. Landmark analysis was performed from median date of sorafenib initiation (d+68). Biology of Blood and Marrow Transplantation 2016 22, S198-S199DOI: (10.1016/j.bbmt.2015.11.588) Copyright © 2016 Terms and Conditions